• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • Articles
    • Children’s Health
    • Diseases & Conditions
    • Healthy Living
    • Men’s Health
    • Sexual Health
    • Women’s Health
  • Books
    • Children’s Health
    • Diseases & Conditions
    • Healthy Living
    • Men’s Health
    • Sexual Health
    • Women’s Health
  • Videos
    • Children’s Health
    • Diseases & Conditions
    • Healthy Living
    • Men’s Health
    • Sexual Health
    • Women’s Health
  • About
  • Contact

Preventive Medicine Daily

Your source for the latest news on preventive medicine and public health

  • News
  • Diseases & Conditions
    • Blood
    • Cancer
    • Circulatory System
    • Congenital
    • Digestive System
    • Ear
    • Endocrine
    • Eye
    • Genitourinary
    • Infectious Diseases
    • Injuries
    • Mental Disorders
    • Metabolic Diseases
    • Musculoskeletal
    • Nervous System
    • Respiratory System
    • Skin
  • Healthy Living
    • Addictions
    • Children’s Health
    • Men’s Health
    • Women’s Health
      • Pregnancy
      • Childbirth
    • Sexual Health
    • Exercise
    • Nutrition
You are here: Home / News / Vaccines / Prevention of Shingles: Better Protection and Better Value With Recombinant Vaccine

Prevention of Shingles: Better Protection and Better Value With Recombinant Vaccine

February 21, 2019 By pmdaily Leave a Comment

CiteULike Link More than 95% of persons aged 50 years or older are latently infected with varicella-zoster virus and are at risk for symptomatic reactivation manifesting as herpes zoster (HZ); lifetime risk for this outcome is about 30%. Risk increases with age and is increased further by immunosuppression and a growing list of comorbid conditions, including diabetes mellitus, chronic kidney disease, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and chronic obstructive pulmonary disease. Herpes zoster causes significant illness and health care costs, especially among those who develop postherpetic neuralgia. In 2006, the U.S. Food and Drug Administration (FDA …

Read the source article at Home | American College of Physicians

Filed Under: Vaccines

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

RSS
Follow by Email
Facebook
Facebook
fb-share-icon
Twitter
Tweet

Recent posts

How Many Carbs Per Day On A Keto Diet?

How many carbs should I eat per day if I am on a keto diet? This is a very frequent question we … [Read More...] about How Many Carbs Per Day On A Keto Diet?

Pairing Protein and Carbs for Better Nutrition

Healthy carb choices plus healthy protein choices work together for a better and more balanced … [Read More...] about Pairing Protein and Carbs for Better Nutrition

Measles cases at ‘alarmingly’ high levels around the world, UNICEF says

Measles cases at ‘alarmingly’ high levels around the world, UNICEF says CNN News February 28, 2019 … [Read More...] about Measles cases at ‘alarmingly’ high levels around the world, UNICEF says

  • A Trial for Prevention of Loss of the Effect of Biological Drugs in Patients With Inflammatory Bowel Disease
  • Mediterranean diets reduce risk of heart disease – new research shows
  • Why being deficient in vitamin C puts you at extreme risk of various diseases
  • Canadian children still not getting enough vitamin D… cancer rates continue to climb

RSS Latest Public Health Headlines

  • WHO and UNICEF issue new guidance to promote breastfeeding in health facilities globally
  • WHO concerned about suspected chemical attacks in Syria
  • Nearly one billion people in Africa to be protected against yellow fever by 2026
  • WHO at 70 - working for better health for everyone, everywhere
  • Donors pledge over US$ 15 million to WHO’s Contingency Fund for Emergencies

Footer

Main Menu

  • Home
  • About
  • Contact

Copyright 2020 PreventiveMedicineDaily.com | Privacy | Terms | DMCA | Disclaimer